http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#Head
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#assertion
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#provenance
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#pubinfo
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#assertion
http://purl.obolibrary.org/obo/DOID_3481
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_3481
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00218
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#association
http://www.w3.org/2000/01/rdf-schema#label
moxifloxacin hydrochloride is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria in the conditions listed below community acquired pneumonia 1 1 skin and skin structure infections uncomplicated 1 2 1 3 complicated intra abdominal infections 1 4 plague 1 5 acute bacterial sinusitis 1 6 acute bacterial exacerbation of chronic bronchitis 1 7 to reduce the development of drug resistant bacteria and maintain the effectiveness of moxifloxacin hydrochloride and other antibacterial drugs moxifloxacin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria 1 8 moxifloxacin hydrochloride is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis staphylococcus aureus klebsiella pneumoniae mycoplasma pneumoniae chlamydophila pneumoniae see clinical studies 14 3 mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs penicillin minimum inhibitory concentrations mic 2 mcg ml 2nd generation cephalosporins for example cefuroxime macrolides tetracyclines and trimethoprim sulfamethoxazole moxifloxacin hydrochloride is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin susceptible staphylococcus aureus streptococcus pyogenes see clinical studies 14 4 moxifloxacin hydrochloride is indicated in adult patients for the treatment of complicated skin and skin structure infections caused by susceptible isolates of methicillin susceptible staphylococcus aureus escherichia coli klebsiella pneumoniae enterobacter cloacae see clinical studies 14 5 moxifloxacin hydrochloride is indicated in adult patients for the treatment of complicated intra abdominal infections ciai including polymicrobial infections such as abscess caused by susceptible isolates of escherichia coli bacteroides fragilis streptococcus anginosus streptococcus constellatus enterococcus faecalis proteus mirabilis clostridium perfringens bacteroides thetaiotaomicron peptostreptococcus see clinical studies 14 6 moxifloxacin hydrochloride is indicated in adult patients for the treatment of plague including pneumonic and septicemic plague due to susceptible isolates of yersinia pestis see clinical studies 14 7 moxifloxacin hydrochloride is indicated in adult patients 18 years of age and older for the treatment of acute bacterial sinusitis abs caused by susceptible isolates of or moxifloxacin hydrochloride is indicated in adult patients 18 years of age and older for the treatment of acute bacterial sinusitis abs caused by susceptible isolates of streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis see clinical studies 14 1 because fluoroquinolones including moxifloxacin hydrochloride have been associated with serious adverse reactions see warnings and precautions 5 moxifloxacin hydrochloride is indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis abecb caused by susceptible isolates of methicillin susceptible or moxifloxacin hydrochloride is indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis abecb caused by susceptible isolates of streptococcus pneumoniae haemophilus influenzae haemophilus parainfluenzae klebsiella pneumoniae staphylococcus aureus moraxella catarrhalis see clinical studies 14 2 because fluoroquinolones including moxifloxacin hydrochloride have been associated with serious adverse reactions see warnings and precautions 5 1 5 13 and for some patients abecb is self limiting reserve moxifloxacin hydrochloride for treatment of abecb in patients who have no alternative treatment options to reduce the development of drug resistant bacteria and maintain the effectiveness of moxifloxacin hydrochloride and other antibacterial drugs moxifloxacin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00218
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#provenance
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#pubinfo
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#sig
http://purl.org/nanopub/x/hasSignature
TTBDBADEs88SSnIcjzn4O1448+bTc11I+CKKVgkdVSYKuo/gc4OSzZ62aifgH0t3ctymHOp5uLIN015/g+GTeGjfRx4YT1/MhaOMQq0l5x5Sz5ZcWzCVbwS/xEtQWJyzDzLFADEl2HavRO/kb1JNNnqIhEK7KToj5O0QWSJ9mBw=
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0
http://purl.org/dc/terms/created
2021-06-12T13:05:05.609+02:00
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs